Drug profile · INN
phenytoin
DILANTIN
phenytoin (DILANTIN) is a sodium channel alpha subunit blocker. Associated with Viatris Pharmaceuticals Co.,. Route of administration: oral. Current US regulatory status: approved.
Drug details — phenytoin
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 4
- Data quality
- 0.84
Quick answer
phenytoin (DILANTIN) is a sodium channel alpha subunit blocker. Associated with Viatris Pharmaceuticals Co.,. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Sodium channel alpha subunit blocker
Primary target: Sodium channel alpha subunit
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| TGA | approved | — |
Recent coverage
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is phenytoin?
phenytoin (DILANTIN) is a sodium channel alpha subunit blocker. Associated with Viatris Pharmaceuticals Co.,. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for phenytoin?
DILANTIN is a marketed brand name for phenytoin. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of phenytoin?
phenytoin has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.